MAÜ GCRIS Standart veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.

Fizyoloji Anabilim Dalı Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.12514/4220

Browse

Browsing Fizyoloji Anabilim Dalı Koleksiyonu by Author "Gökdemir.Gül Şahika"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    The Effect of Gliclazide use on BDNF and NGF Levels in Rats with Diabetes Mellitus
    (2023) Gökdemir, Gül Şahika; Baylan,Mukadder
    Objective: In this study, the effects of gliclazides, a second generation sulfonylurea group, on BDNF and NGF plasma levels, which are considered neurodegeneration biomarkers, will be examined. When designing our study, we assumed that gliazides might have positive neuronal effects. Thus, the possible positive effects of gliclazide will be emphasized in our study. Methods: In the experiment, 21 adult male Wistar-Albino rats were used. Serum BDNF and NGF levels were determined by analyzing with enzyme-linked immunosorbent assay kit in accordance with the recommendations. Results: BDNF levels were significantly lower in gliclazide-treated diabetic rats and nonmedicated diabetic rats compared to the healthy control group (p=0.017, p<0.001, respectively). Although the BDNF level of rats with diabetes given gliclazide was increased compared to rats with and without diabetes, this difference was not significant (p=0.107). Similarly, NGF levels were significantly lower in rats given gliclazide (p=0.009) and diabetic rats not given gliclazide (p=0.001) compared to the healthy control group. When the diabetic groups were compared among themselves, although the NGF level was increased in the gliclazide group, this difference was not statistically significant (p=0.638). The differences between the groups were significant in cyclic AMP regulatory element binding (p<0.001), c-FOS (p<0.001), amyloid precursor protein (p<0.001), B-SECRETASE1 (p=0.004), and doublecortin (p<0.001) levels. Conclusion: As a result, serum BDNF and NGF levels were significantly higher in non-diabetic healthy control group rats than in diabetic rats. While low serum levels of BDNF and NGF neurotrophins, which increase in neurodegeneration, were observed in diabetic rats, this level was observed to be higher in diabetic rats given gliclazide.
  • Thumbnail Image
    Article
    EFFECT OF METFORMIN ON MUSCLE ATROPHY IN EXPERIMENTAL DIABETIC RATS
    (2023) Gökdemir, Gül Şahika; Gökdemir, Mehmet Tahir; Gökdemir, Mehmet Tahir; Baylan,Mukadder
    Background: Although first-line biguanide metformin is frequently administered to T2DM patients, the effects of long-term use on muscle are unknown. This study aimed to examine the effect of metformin-treated diabetes on muscle atrophy in experimental diabetic rats. Materials and methods: Twenty-one Wistar albino male rats in 3 groups were included in our research. Insulin resistance HOMA-IR, mTOR, and Myostatin levels and gastrocnemius weight were measured. Results: Myostatin level was significantly higher in the non-medicated diabetes group than in the healthy control group (p<0.001). Moreover, myostatin level was significantly lower in the metformin group (p=0.001). The weight of gastrocnemius was significantly lower in both the metformin-treated and non-metformin-treated diabetic groups compared to the control group (p<0.001 for both groups). Moreover, the gastrocnemius weight was significantly higher in the metformin group than in the non-medicated group (p=0.004). The HOME-IR level had a significantly negative correlation with the mTOR level (R=-0.783; P<0.001) and a positive correlation with the myostatin level (R=0.622; P=0.003). Conclusion: Our evidence and data support that metformin may be effective in preventing muscle wasting. To conclude, this study showed that metformin has anti-atrophic effects on muscles in diabetes and that metformin can prevent muscle mass loss.